1. Qin Q, Chang Y, Wang D, et al., 2011, TACI Ig Induces Immune Balance of Th Cells in MLN via BLyS/APRIL Receptors Signaling in Rats with Adjuvant Induced Arthritis. Int Immunopharmacol, 11(12): 2167–2175.
2. Shabgah AG, Shariati Sarabi Z, Tavakkol Afshari J, et al., 2019, The Role of BAFF and APRIL in Rheumatoid Arthritis. J Cell Physiol, 234(10): 17050–17063.
3. Gross JA, Johnston J, Mudri S, et al., 2000, TACI and BCMA Are Receptors for a TNF Homologue Implicated in B Cell Autoimmune Disease. Nature, 404(6781): 995–999.
4. Marsters SA, Yan M, Pitti RM, et al., 2000, Interaction of the TNF Homologues BLyS and APRIL with the TNF Receptor Homologues BCMA and TACI. Curr Biol, 10(13): 785–788.
5. Mackay F, Silveira P, Brink R, 2007, B Cells and the BAFF/APRIL Axis: Fast Forward on Autoimmunity and Signaling. Curr Opin Immunol, 19(3): 327–336.
6. Bossen C, Schneider P, 2006, BAFF, APRIL and Their Receptors: Structure, Function and Signaling. Semin Immunol, 18(5): 263–275.
7. Eslami M, Schneider P, 2021, Function, Occurrence and Inhibition of Different Forms of BAFF. Curr Opin Immunol, 71: 75–80.
8. Schneider P, MacKay F, Steiner V, et al., 1999, BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. J Exp Med, 189(11): 1747–1756.
9. Moore PA, Belvedere O, Orr A, et al., 1999, BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator. Science, 285(5425): 260–263.
10. Zhang X, Park CS, Yoon SO, et al., 2005, BAFF Supports Human B Cell Differentiation in the Lymphoid Follicles Through Distinct Receptors. Int Immunol, 17(6): 779–788.
11. Hahne M, Kataoka T, Schroter M, et al., 1998, APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth. J Exp Med, 188(6): 1185–1190.
12. Benson MJ, Dillon SR, Castigli E, et al., 2008, Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL. J Immunol, 180(6): 3655–3659.
13. Castigli E, Wilson SA, Elkhal A, et al., 2007, Transmembrane Activator and Calcium Modulator and Cyclophilin Ligand Interactor Enhances CD40 Driven Plasma Cell Differentiation. J Allergy Clin Immunol, 120(4): 885–891.
14. Dillon SR, Gross JA, Ansell SM, et al., 2006, An APRIL to Remember: Novel TNF Ligands as Therapeutic Targets. Nat Rev Drug Discov, 5(3): 235–246.
15. Litinskiy MB, Nardelli B, Hilbert DM, et al., 2002, DCs Induce CD40 Independent Immunoglobulin Class Switching Through BLyS and APRIL. Nat Immunol, 3(9): 822–829.
16. McCarron MJ, Park PW, Fooksman DR., 2017, CD138 Mediates Selection of Mature Plasma Cells by Regulating Their Survival. Blood, 129(20): 2749–2759.
17. Liu H, Liu J, Zhang Z., 2021, Application Value of TNF-α, IL-6, BlyS, and APRIL Levels in the Diagnosis and Prognosis Evaluation of Viral Encephalitis. Stroke and Nervous Diseases, 28(3): 321–325.
18. Thompson JS, Bixler SA, Qian F, et al., 2001, BAFFR, a Newly Identified TNF Receptor that Specifically Interacts with BAFF. Science, 293(5537): 2108–2111.
19. Wu Y, Bressette D, Carrell JA, et al., 2000, Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI is a High Affinity Receptor for TNF Family Members APRIL and BLyS. J Biol Chem, 275(45): 35478–35485.
20. Thompson JS, Schneider P, Kalled SL, et al., 2000, BAFF Binds to the Tumor Necrosis Factor ReceptorLike Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population. J Exp Med, 192(1): 129–135.
21. Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, et al., 2019, The Role of BAFF and APRIL in Rheumatoid Arthritis. J Cell Physiol, 234(10): 17050–17063.
22. Darce JR, Arendt BK, Wu X, et al., 2007, Regulated Expression of BAFF-Binding Receptors During Human B Cell Differentiation. J Immunol, 179(11): 7276–7286.
23. Kampa M, Notas G, Stathopoulos EN, et al., 2020, The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, with a Special Focus on Breast Cancer. Front Oncol, 10: 827.
24. Shi F, Xue R, Zhou X, et al., 2021, Telitacicept as a BLyS/APRIL Dual Inhibitor for Autoimmune Disease. Immunopharmacol Immunotoxicol, 43(6): 666–673.
25. Vincent FB, Morand EF, Schneider P, et al., 2014, The BAFF/APRIL System in SLE Pathogenesis. Nat Rev Rheumatol, 10(6): 365–373.
26. Mackay F, Schneider P, 2008, TACI, an Enigmatic BAFF/APRIL Receptor, with New Unappreciated Biochemical and Biological Properties. Cytokine Growth Factor Rev, 19(3–4): 263–276.
27. Walters S, Webster KE, Sutherland A, et al., 2009, Increased CD4+ Foxp3+ T Cells in BAFF-Transgenic Mice Suppress T Cell Effector Responses. J Immunol, 182(2): 793–801.
28. Bloom DD, Reshetylo S, Nytes C, et al., 2018, Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity. J Immunother, 41(5): 213–223.
29. Marino E, Villanueva J, Walters S, et al., 2009, CD4(+)CD25(+) T-Cells Control Autoimmunity in the Absence of B-cells. Diabetes, 58(7): 1568–1577.
30. Chang SK, Arendt BK, Darce JR, et al., 2006, A Role for BLyS in the Activation of Innate Immune Cells. Blood, 108(8): 2687–2694.
31. Chang SK, Mihalcik SA, Jelinek DF, 2008, B Lymphocyte Stimulator Regulates Adaptive Immune Responses by Directly Promoting Dendritic Cell Maturation. J Immunol, 180(11): 7394–7403.
32. Chen Y, Yang M, Long D, et al., 2020, Abnormal Expression of BAFF and its Receptors in Peripheral Blood and Skin Lesions from Systemic Lupus Erythematosus Patients. Autoimmunity, 53(4): 192–200.
33. Schuh E, Musumeci A, Thaler FS, et al., 2017, Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen Upon TLR Engagement. J Immunol, 198(8): 3081–3088.
34. Tai YT, Mayes PA, Acharya C, et al., 2014, Novel Anti-B-Cell Maturation Antigen Antibody-Drug Conjugate (GSK2857916) Selectively Induces Killing of Multiple Myeloma. Blood, 123(20): 3128–3138.
35. Ullah MA, Mackay F., 2023, The BAFF-APRIL System in Cancer. Cancers, 15(6): 1791.
36. Mackay F, Woodcock SA, Lawton P, et al., 1999, Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations. J Exp Med, 190(11): 1697–1710.
37. Zhang Y, Li J, Zhou N, et al., 2017, The Unknown Aspect of BAFF: Inducing IL-35 Production by a CD5(+)CD1d(hi) FcγRIIb(hi) Regulatory B-Cell Subset in Lupus. J Invest Dermatol, 137(12): 2532–2543.
38. Dong X, Qin J, Ma J, et al., 2019, BAFF Inhibits Autophagy Promoting Cell Proliferation and Survival by Activating Ca(2+)-CaMKII-Dependent Akt/mTOR Signaling Pathway in Normal and Neoplastic B-Lymphoid Cells. Cell Signal, 53: 68–79.
39. Hua C, Audo R, Yeremenko N, et al., 2016, A Proliferation Inducing Ligand (APRIL) Promotes IL-10 Production and Regulatory Functions of Human B Cells. J Autoimmun, 73: 64–72.
40. Fehres CM, van Uden NO, Yeremenko NG, et al., 2019, APRIL Induces a Novel Subset of IgA(+) Regulatory B Cells that Suppress Inflammation Via Expression of IL-10 and PD-L1. Front Immunol, 10: 1368.
41. Yang M, Sun L, Wang S, et al., 2010, Novel Function of B Cell-Activating Factor in the Induction of IL-10-Producing Regulatory B Cells. J Immunol, 184(7): 3321–3325.
42. Belnoue E, Pihlgren M, McGaha TL, et al., 2008, APRIL is Critical for Plasmablast Survival in the Bone Marrow and Poorly Expressed by Early-Life Bone Marrow Stromal Cells. Blood, 111(5): 2755–2764.
43. Hardenberg G, van Bostelen L, Hahne M, et al., 2008, Thymus-Independent Class Switch Recombination is Affected by APRIL. Immunol Cell Biol, 86(6): 530–534.
44. Garcillan B, Figgett WA, Infantino S, et al., 2018, Molecular Control of B-Cell Homeostasis in Health and Malignancy. Immunol Cell Biol, 96(5): 453–462.
45. Rowland SL, Leahy KF, Halverson R, et al., 2010, BAFF Receptor Signaling Aids the Differentiation of Immature B Cells into Transitional B Cells Following Tonic BCR Signaling. J Immunol, 185(8): 4570–4581.
46. Müller-Winkler J, Mitter R, Rappe JCF, et al., 2021, Critical Requirement for BCR, BAFF, and BAFFR in Memory B Cell Survival. J Exp Med, 218(2): e20191393.
47. Patke A, Mecklenbrauker I, Tarakhovsky A., 2004, Survival Signaling in Resting B Cells. Curr Opin Immunol, 16(2): 251–255.
48. Ma N, Zhang Y, Liu Q, et al., 2017, B Cell Activating Factor (BAFF) Selects IL-10-Producing B Cells Over IL-10+ B Cells During Inflammatory Responses. Mol Immunol, 85: 18–26.
49. Schiemann B, Gommerman JL, Vora K, et al., 2001, An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway. Science, 293(5537): 2111–2114.
50. Samy E, Wax S, Huard B, et al., 2017, Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. Int Rev Immunol, 36(1): 3–19.
51. Kaegi C, Steiner UC, Wuest B, et al., 2020, Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Front Immunol, 11: 433.
52. Tsuji S, Cortesao C, Bram RJ, et al., 2011, TACI Deficiency Impairs Sustained Blimp-1 Expression in B Cells Decreasing Long-Lived Plasma Cells in the Bone Marrow. Blood, 118(22): 5832–5839.
53. O’Connor BP, Raman VS, Erickson LD, et al., 2004, BCMA is Essential for the Survival of Long-Lived Bone Marrow Plasma Cells. J Exp Med, 199(1): 91–98.
54. Stein JV, Lopez-Fraga M, Elustondo FA, et al., 2002, APRIL Modulates B and T Cell Immunity. J Clin Invest, 109(12): 1587–1598.
55. Huard B, Schneider P, Mauri D, et al., 2001, T Cell Costimulation by the TNF Ligand BAFF. J Immunol, 167(11): 6225–6231.
56. Yu G, Boone T, Delaney J, et al., 2000, APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity. Nat Immunol, 1(3): 252–256.
57. Hu S, Wang R, Zhang M, et al., 2019, BAFF Promotes T Cell Activation Through the BAFF-BAFF-R-PI3K-Akt Signaling Pathway. Biomed Pharmacother, 114: 108796.
58. Ng LG, Sutherland AP, Newton R, et al., 2004, B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells. J Immunol, 173(2): 807–817.
59. de Graaf CA, Choi J, Baldwin TM, et al., 2016, Haemopedia: An Expression Atlas of Murine Hematopoietic Cells. Stem Cell Reports, 7(3): 571–582.
60. Suzuki K, Setoyama Y, Yoshimoto K, et al., 2008, Effect of Interleukin-2 on Synthesis of B Cell Activating Factor Belonging to the Tumor Necrosis Factor Family (BAFF) in Human Peripheral Blood Mononuclear Cells. Cytokine, 44(1): 44–48.
61. Quah PS, Sutton V, Whitlock E, et al., 2022, The Effects of B-Cell-Activating Factor on the Population Size, Maturation and Function of Murine Natural Killer Cells. Immunol Cell Biol, 100(10): 761–776.
62. Zhang W, Wen L, Huang X, et al., 2008, hsBAFF Enhances Activity of NK Cells by Regulation of CD4(+) T Lymphocyte Function. Immunol Lett, 120(1–2): 96–102.
63. Fan Y, Gao D, Zhang Z., 2022, Telitacicept, a Novel Humanized, Recombinant TACI-Fc Fusion Protein, for the Treatment of Systemic Lupus Erythematosus. Drugs Today (Barc), 58(1): 23–32.
64. Fernandez Matilla M, Grau Garcia E, Fernandez-Llanio Comella N, et al., 2019, Increased Interferon-1Alpha, Interleukin-10 and BLyS Concentrations as Clinical Activity Biomarkers in Systemic Lupus Erythematosus. MClin (Barc), 153(6): 225–231.
65. Yoshimoto K, Suzuki K, Takei E, et al., 2020, Elevated Expression of BAFF Receptor, BR3, on Monocytes Correlates with B Cell Activation and Clinical Features of Patients with Primary Sjogren’s Syndrome. Arthritis Res Ther, 22(1): 157.
66. Pers JO, Daridon C, Devauchelle V, et al., 2005, BAFF Overexpression is Associated with Autoantibody Production in Autoimmune Diseases. Ann N Y Acad Sci, 1050: 34–39.
67. Becker-Merok A, Nikolaisen C, Nossent HC., 2006, B-Lymphocyte Activating Factor in Systemic Lupus Erythematosus and Rheumatoid Arthritis in Relation to Autoantibody Levels, Disease Measures and Time. Lupus, 15(9): 570–576.
68. Wang H, Wang K, Zhong X, et al., 2012, Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse. J Clin Immunol, 32(5): 1007–1011.
69. Ashida S, Kondo T, Fujii C, et al., 2022, Association of Cerebrospinal Inflammatory Profile with Radiological Features in Newly Diagnosed Treatment-Naive Patients with Multiple Sclerosis. Front Neurol, 13: 1012857.
70. Zingaropoli MA, Pasculli P, Tartaglia M, et al., 2023, Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk. Biology (Basel), 12(4): 587.
71. Krumbholz M, Faber H, Steinmeyer F, et al., 2008, Interferon-Beta Increases BAFF Levels in Multiple Sclerosis: Implications for B Cell Autoimmunity. Brain, 131(Pt 6): 1455–1463.
72. Piazza F, DiFrancesco JC, Fusco ML, et al., 2010, Cerebrospinal Fluid Levels of BAFF and APRIL in Untreated Multiple Sclerosis. J Neuroimmunol, 220(1-2): 104–107.
73. Schubert RD, Hu Y, Kumar G, et al., 2015, IFN-Beta Treatment Requires B Cells for Efficacy in Neuroautoimmunity. J Immunol, 194(5): 2110–2116.
74. Rojas OL, Probstel AK, Porfilio EA, et al., 2019, Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell, 176(3): 610–624.
75. Vaknin-Dembinsky A, Brill L, Orpaz N, et al., 2010, Preferential Increase of B-Cell Activating Factor in the Cerebrospinal Fluid of Neuromyelitis Optica in a White Population. Mult Scler, 16(12): 1453–1457.
76. Quan C, Yu H, Qiao J, et al., 2013, Impaired Regulatory Function and Enhanced Intrathecal Activation of B Cells in Neuromyelitis Optica: Distinct from Multiple Sclerosis. Mult Scler, 19(3): 289–298.
77. Wang S, Yang T, Wan J, et al., 2017, Elevated C-X-C Motif Ligand 13 and B-Cell-Activating Factor Levels in Neuromyelitis Optica During Remission. Brain Behav, 7(4): e00648.
78. Baert L, Marignier R, Lassmann HP, et al., 2021, Case Report: Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica. Front Neurol, 12: 721877.
79. Kang SY, Kang CH, Lee KH., 2016, B-Cell-Activating Factor is Elevated in Serum of Patients with Myasthenia Gravis. Mcle Nerve, 54(6): 1030–1033.
80. Zhou Y, Yan C, Gu X, et al., 2021, Short-Term Effect of Low-Dose Rituximab on Myasthenia Gravis with Muscle-Specific Tyrosine Kinase Antibody. Muscle Nerve, 63(6): 824–830.
81. Sobieszczuk E, Szczudlik P, Kubiszewska J, et al., 2021, Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids. Arch Immunol Ther Exp (Warsz), 69(1): 22.
82. Deng H, Wang J, Kong X, et al., 2019, Associations of BAFF rs2893321 Polymorphisms with Myasthenia Gravis Susceptibility. BMC Med Genet, 20(1): 168.
83. Uzawa A, Kanai T, Kawaguchi N, et al., 2016, Changes in Inflammatory Cytokine Networks in Myasthenia Gravis. Sci Rep, 6: 25886.
84. Uzawa A, Kuwabara S, Suzuki S, et al., 2021, Roles of Cytokines and T Cells in the Pathogenesis of Myasthenia Gravis. Clin Exp Immunol, 203(3): 366–374.
85. Schneider-Gold C, Gilhus NE, 2021, Advances and Challenges in the Treatment of Myasthenia Gravis. Ther Adv Neurol Disord, 14: 17562864211065406.
86. Schrezenmeier E, Jayne D, Dorner T, 2018, Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. J Am Soc Nephrol, 29(3): 741–758.
87. Magliozzi R, Marastoni D, Calabrese M, 2020, The BAFF/APRIL System as a Therapeutic Target in Multiple Sclerosis. Expert Opin Ther Targets, 24(11): 1135–1145.
88. Hewett K, Sanders DB, Grove RA, et al., 2018, Randomized Study of Adjunctive Belimumab in Participants with Generalized Myasthenia Gravis. Neurology, 90(16): e1425–e1434.
89. Dalakas MC, 2019, Immunotherapy in Myasthenia Gravis in the Era of Biologics. Nat Rev Neurol, 15(2): 113–124.
90. Hehir MK, Hobson-Webb LD, Benatar M, et al., 2017, Rituximab as Treatment for Anti-MuSK Myasthenia Gravis: Multicenter Blinded Prospective Review. Neurology, 89(10): 1069–1077.
91. Greenwald M, Szczepanski L, Kennedy A, et al., 2014, A 52-Week, Open-Label Study Evaluating the Safety and Efficacy of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, for Rheumatoid Arthritis. Arthritis Res Ther, 16(4): 415.
92. Gordon C, Bassi R, Chang P, et al., 2019, Integrated Safety Profile of Atacicept: An Analysis of Pooled Data from the Atacicept Clinical Trial Programme. Rheumatol Adv Pract, 3(2): rkz021.
93. Kappos L, Hartung HP, Freedman MS, et al., 2014, Atacicept in Multiple Sclerosis (ATAMS): A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial. Lancet Neurol, 13(4): 353–363.
94. Sergott RC, Bennett JL, Rieckmann P, et al., 2015, ATON: Results from a Phase II Randomized Trial of the B-Cell-Targeting Agent Atacicept in Patients with Optic neuritis. J Neurol Sci, 351(1–2): 174–178.
95. Schneider P, Takatsuka H, Wilson A, et al., 2001, Maturation of Marginal Zone and Follicular B Cells Requires B Cell Activating Factor of the Tumor Necrosis Factor Family and is Independent of B Cell Maturation Antigen. J Exp Med, 194(11): 1691–1697.
96. Gross JA, Dillon SR, Mudri S, et al., 2001, TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease. Impaired B cell Maturation in Mice Lacking BLyS. Immunity, 15(2): 289–302.
97. Haselmayer P, Vigolo M, Nys J, et al., 2017, A Mouse Model of Systemic Lupus Erythematosus Responds Better to Soluble TACI than to Soluble BAFFR, Correlating with Depletion of Plasma Cells. Eur J Immunol, 47(6): 1075–1085.
98. Cai J, Gao D, Liu D, et al., 2023, Telitacicept for Autoimmune Nephropathy. Front Immunol, 14: 1169084.
99. Ma X, Fu X, Cui B, et al., 2022, Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature. Tohoku J Exp Med, 258(3): 219–223.
100. Ding J, Cai Y, Deng Y, et al., 2021, Telitacicept Following Plasma Exchange in the Treatment of Subjects with Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study. Front Neurol, 12: 596791.
101. Ding J, Jiang X, Cai Y, et al., 2022, Telitacicept Following Plasma Exchange in the Treatment of Subjects with Recurrent Neuromyelitis Optica Spectrum Disorders: a Single-Center Single-Arm, Open-Label Study. CNS Neurosci Ther, 28(10): 1613–1623.